These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 16098070)

  • 1. Zoledronate synergises with imatinib mesylate to inhibit Ph primary leukaemic cell growth.
    Segawa H; Kimura S; Kuroda J; Sato K; Yokota A; Kawata E; Kamitsuji Y; Ashihara E; Yuasa T; Fujiyama Y; Ottmann OG; Maekawa T
    Br J Haematol; 2005 Aug; 130(4):558-60. PubMed ID: 16098070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The third-generation bisphosphonate zoledronate synergistically augments the anti-Ph+ leukemia activity of imatinib mesylate.
    Kuroda J; Kimura S; Segawa H; Kobayashi Y; Yoshikawa T; Urasaki Y; Ueda T; Enjo F; Tokuda H; Ottmann OG; Maekawa T
    Blood; 2003 Sep; 102(6):2229-35. PubMed ID: 12763930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells.
    D'Asaro M; La Mendola C; Di Liberto D; Orlando V; Todaro M; Spina M; Guggino G; Meraviglia S; Caccamo N; Messina A; Salerno A; Di Raimondo F; Vigneri P; Stassi G; Fourniè JJ; Dieli F
    J Immunol; 2010 Mar; 184(6):3260-8. PubMed ID: 20154204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sorafenib induces apoptosis specifically in cells expressing BCR/ABL by inhibiting its kinase activity to activate the intrinsic mitochondrial pathway.
    Kurosu T; Ohki M; Wu N; Kagechika H; Miura O
    Cancer Res; 2009 May; 69(9):3927-36. PubMed ID: 19366808
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance to imatinib of bcr/abl p190 lymphoblastic leukemia cells.
    Mishra S; Zhang B; Cunnick JM; Heisterkamp N; Groffen J
    Cancer Res; 2006 May; 66(10):5387-93. PubMed ID: 16707466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ABT-737 is a useful component of combinatory chemotherapies for chronic myeloid leukaemias with diverse drug-resistance mechanisms.
    Kuroda J; Kimura S; Andreeff M; Ashihara E; Kamitsuji Y; Yokota A; Kawata E; Takeuchi M; Tanaka R; Murotani Y; Matsumoto Y; Tanaka H; Strasser A; Taniwaki M; Maekawa T
    Br J Haematol; 2008 Jan; 140(2):181-90. PubMed ID: 18028486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-leukemic activity of valproic acid and imatinib mesylate on human Ph+ ALL and CML cells in vitro.
    Kircher B; Schumacher P; Petzer A; Hoflehner E; Haun M; Wolf AM; Nachbaur D; Gastl G
    Eur J Haematol; 2009 Jul; 83(1):48-56. PubMed ID: 19226363
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
    Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of imatinib mesylate as maintenance therapy in adults with acute lymphoblastic leukemia in first complete remission.
    Potenza L; Luppi M; Riva G; Marasca R; Martinelli S; Torelli G
    Haematologica; 2005 Sep; 90(9):1275-7. PubMed ID: 16154854
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imatinib compared with chemotherapy as front-line treatment of elderly patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL).
    Ottmann OG; Wassmann B; Pfeifer H; Giagounidis A; Stelljes M; Dührsen U; Schmalzing M; Wunderle L; Binckebanck A; Hoelzer D;
    Cancer; 2007 May; 109(10):2068-76. PubMed ID: 17429836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia.
    Chen R; Gandhi V; Plunkett W
    Cancer Res; 2006 Nov; 66(22):10959-66. PubMed ID: 17108134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy.
    Yanada M; Sugiura I; Takeuchi J; Akiyama H; Maruta A; Ueda Y; Usui N; Yagasaki F; Yujiri T; Takeuchi M; Nishii K; Kimura Y; Miyawaki S; Narimatsu H; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    Br J Haematol; 2008 Nov; 143(4):503-10. PubMed ID: 18986386
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antileukemic activity of lysophosphatidic acid acyltransferase-beta inhibitor CT32228 in chronic myelogenous leukemia sensitive and resistant to imatinib.
    La Rosée P; Jia T; Demehri S; Härtel N; de Vries P; Bonham L; Hollenback D; Singer JW; Melo JV; Druker BJ; Deininger MW
    Clin Cancer Res; 2006 Nov; 12(21):6540-6. PubMed ID: 17085669
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate.
    Nguyen TK; Rahmani M; Gao N; Kramer L; Corbin AS; Druker BJ; Dent P; Grant S
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2239-47. PubMed ID: 16609040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imatinib mesylate: A designer drug.
    Panigrahi I; Naithani R
    J Assoc Physicians India; 2006 Mar; 54():203-6. PubMed ID: 16800347
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CML clonal evolution with resistance to single agent imatinib therapy.
    Swords R; Quinn J; Fay M; O'Donnell R; Goldman J; Murphy PT
    Clin Lab Haematol; 2005 Oct; 27(5):347-9. PubMed ID: 16178920
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The treatment of pediatric Philadelphia positive (Ph+) leukemias in the imatinib era.
    Burke MJ; Willert J; Desai S; Kadota R
    Pediatr Blood Cancer; 2009 Dec; 53(6):992-5. PubMed ID: 19621426
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group.
    Yanada M; Takeuchi J; Sugiura I; Akiyama H; Usui N; Yagasaki F; Kobayashi T; Ueda Y; Takeuchi M; Miyawaki S; Maruta A; Emi N; Miyazaki Y; Ohtake S; Jinnai I; Matsuo K; Naoe T; Ohno R;
    J Clin Oncol; 2006 Jan; 24(3):460-6. PubMed ID: 16344315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
    Kantarjian H; O'Brien S; Talpaz M; Borthakur G; Ravandi F; Faderl S; Verstovsek S; Rios MB; Shan J; Giles F; Cortes J
    Cancer; 2007 Apr; 109(8):1556-60. PubMed ID: 17342766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.